Igniting Endogenous Calcipoptosis via ER‐Mitochondrial Calcium Shuttle Hijacking for Potent Antitumor Immunity
Advanced Materials · 2026-05 · 38 (26)
DOI: 10.1002/adma.202518631 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 04.04.2026. Verfasst von Chen Cheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Chongqing Key Laboratory of Ultrasound Molecular Imaging and Therapy, Ultrasound Department of the Second Affiliated Hospital of Chongqing Medical Un…. Hauptthemen laut MEDLINE: Mitochondria, Endoplasmic Reticulum, Calcium. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing, Kuanren Talents Program of the Second Affiliated Hospital of Chongqing Medical University.
Abstract (Originalsprache)
The maintenance of intracellular calcium ion (Ca 2 + ) homeostasis plays a pivotal role in regulating both cellular survival and immunoregulatory pathways. However, achieving safe and precise manipulation of these messenger ions to engineer next‐generation antitumor immunotherapies remains a formidable challenge. Here, we reveal an organelle crosstalk paradigm that harnesses innate Ca 2+ dynamics to drive calcipoptosis‐mediated antitumor immunity, bypassing the limitations of conventional exogenous calcium‐dependent strategies. A modular peptide‐programmed nanoagonist was designed to activate self‐supplied calcium influx between Ca 2+ ‐rich and Ca 2+ ‐sensitive organelles by inducing endoplasmic reticulum stress and opening mitochondrial calcium transport channels under ultrasound irradiation. Moreover, the targeted dysfunction of dual‐organelles leads to the activation of the caspase‐dependent apoptotic pathway and the release of a cascade of damage‐associated molecular patterns to promote dendritic cell maturation and cytotoxic T‐cell infiltration. Additionally, Ca 2+ dysregulation polarizes macrophages into a pro‐inflammatory phenotype and stiffens cancer cells to establish biochemical and mechanical immunosurveillance. The nanoagonist demonstrated potent ablation of primary tumors and suppression of metastatic growth in breast and liver cancer models. Overall, this work enables customizable subcellular bioenergetic disruption without systemic toxicity risks, which pioneers a translatable strategy that redefines the frontier of calcium‐based immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chongqing Key Laboratory of Ultrasound Molecular Imaging and Therapy, Ultrasound Department of the Second Affiliated Hospital of Chongqing Medical University, Chongqing, P. R. China.
- General Practice Department of Chongqing General Hospital, Chongqing, P. R. China.
ORCID-Profile: Weixi Jiang, Jianli Ren
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
- Kuanren Talents Program of the Second Affiliated Hospital of Chongqing Medical University
- Chongqing Graduate Student Research Innovation Project
- Natural Science Foundation of Chongqing Municipality
Zitieren
APA
Cheng, C., Hou, S., An, H., Du, C., Wang, Z., Ran, H., Zhou, Z., Jiang, W., & Ren, J. (2026). Igniting Endogenous Calcipoptosis via ER‐Mitochondrial Calcium Shuttle Hijacking for Potent Antitumor Immunity. Advanced Materials, 38(26). https://doi.org/10.1002/adma.202518631
Vancouver
Cheng C, Hou S, An H, Du C, Wang Z, Ran H, et al. Igniting Endogenous Calcipoptosis via ER‐Mitochondrial Calcium Shuttle Hijacking for Potent Antitumor Immunity. Advanced Materials. 2026;38(26). doi:10.1002/adma.202518631
BibTeX
@article{Cheng2026,
author = {Cheng, Chen and Hou, Shengzhe and An, Hongjin and Du, Chier and Wang, Zhigang and Ran, Haitao and Zhou, Zhiyi and Jiang, Weixi and Ren, Jianli},
title = {Igniting Endogenous Calcipoptosis via ER‐Mitochondrial Calcium Shuttle Hijacking for Potent Antitumor Immunity},
journal = {Advanced Materials},
year = {2026},
volume = {38},
number = {26},
doi = {10.1002/adma.202518631}
}
EUVIMED